Strides Pharma Science share news and announcements
NSE: STARBSE: 532531Pharmaceuticals & BiotechnologySmall Cap
Formerly Strides Shasun
Last close ₹1,014.80up ₹16.40 (1.64%)BSE ₹1,012.15
Share price at the NSE close on 23 Oct 2026. Previous close ₹998.40.
52-week range of traded prices to 23 Oct 2026
₹768.65Low, 29 Jan 2026₹1,260.90High, 21 Sep 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹9,354 Cr580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- 15.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- 3.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.49%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 21.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,12,38541.2% delivered
Strides Pharma Science share news and announcements
1,456 announcements, routine notices left out, newest first. Page 21 of 30.
Apr 2013
Mar 2013
13 Mar · Business
Company has allotted 42,150 fully paid equity shares of Rs. 10/- each on conversion of employee stock options under Strides Arcolab ESOP Schemes. Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs. 590,061,710/- consisting of 59,006,171 equity shares of Rs. 10/- each to Rs. 590,483,210/- consisting of 59,048,321 equity shares of Rs. 10/- each.1 Mar · Business
Company has allotted 120,800 fully paid equity shares of Rs. 10/- each on conversion of employee stock options under Strides Arcolab ESOP Schemes. Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs. 588,037,210/- consisting of 58,803,721 equity shares of Rs. 10/- each to Rs. 589,245,210/- consisting of 58,924,521 equity shares of Rs. 10/- each.
Feb 2013
28 Feb · Dividend
Dividend payout date will be June 05, 2013, subject to the approval of dividend by the shareholders of the Company at the ensuing Annual General Meeting on May 31, 2013.28 Feb · Dividend
Board of Directors of the Company at its meeting held on February 28, 2013 has recommended dividend at 20% viz., Rs 2.00 per share for the year ended December 31, 2012.20 Feb · Board meeting
To consider inter-alia, the audited financial results of the Company for the financial year ended December 31, 2012 and recommendation of dividend, if any.19 Feb · Business
Company has allotted 81,650 fully paid equity shares of Rs. 10/- each on conversion of employee stock options under Strides Arcolab ESOP Schemes. Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs. 589,245,210/- consisting of 58,924,521 equity shares of Rs. 10/- each to Rs. 590,061,710/- consisting of 59,006,171 equity shares of Rs. 10/- each.12 Feb · Business
Company has allotted 120,800 fully paid equity shares of Rs. 10/- each on conversion of employees stock options under Strides Arcolab ESOP Schemes. Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs. 588,037,210/- consisting of 58,803,721 equity shares of Rs. 10/- each to Rs. 589,245,210/- consisting of 58,924,521 equity shares of Rs. 10/- each.8 Feb · News Verification
News Verification : The media had reports that the potential sale of injectible medicine unit of Strides Arcolab Limited may get delayed or cancelled. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Strides Arcolab Limited has vide its letter inter-alia stated, "We wish to clarify that the news report is not based on any information from the Company and is purely speculative in nature."
Jan 2013
Dec 2012
Nov 2012
29 Nov · News Verification
News Verification : The media had reports that Strides Arcolab Limited will sell its injectible unit. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Strides Arcolab Limited has vide its letter inter-alia stated, "We wish to clarify that no material event requiring intimation to Stock Exchanges as per clause 36 of the Listing Agreement has occurred".
Oct 2012
26 Oct · Rating
India Ratings & Research (India Ratings), a Fitch Group Company, has upgraded Strides Arcolab Limited's (Strides) Long-Term Issuer rating to 'IND BBB+' from 'IND BBB-'. The Outlook is Stable. The upgrade reflects India Ratings' expectation of a sustained improvement in Strides' financial leverage (adjusted debt / EBITDA) in the medium term.19 Oct · Business
Company has allotted 65,000 fully paid equity shares of Rs.10/- each on conversion of employee stock options under Strides Arcolab ESOP Scheme. Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs.587,387,210/- consisting of 58,738,721 equity shares of Rs.10/- each to Rs.588,037,210/- consisting of 58,803,721 equity shares of Rs.10/- each.15 Oct · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended September 30, 2012.
Sep 2012
26 Sep · Business
Company has allotted 15,000 fully paid equity shares of Rs.10/- each on conversion of employee stock options under Strides Arcolab ESOP Scheme. Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs.587,237,210/- consisting of 58,723,721 equity shares of Rs.10/- each to Rs.587,387,210/- consisting of 58,738,721equity shares of Rs.10/- each.10 Sep · Business
Company has allotted 27,250 fully paid equity shares of Rs.10/- each on conversion of employee stock options under Strides Arcolab ESOP Scheme. Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs.586,964,710/- consisting of 58,696,471 equity shares of Rs.10/- each to Rs.587,237,210/- consisting of 58,723,721 equity shares of Rs.10/- each.
Aug 2012
Jul 2012
30 Jul · Disclosure
Remuneration Committee of the Company has granted 50,000 options to Mr. S Sridhar, Independent Director of the Company at Rs. 609.80 per option under the Strides Arcolab ESOP 2008 (Director) Scheme. The shares covered by such option are 50,000 equity shares of Rs.10/- each. The vesting period of these options is in a phased manner over a period of three years. The options may be exercised within a period of 30 days from the date of vesting.